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Abstract ʹ͹
Host cell differentiation-dependent regulation of human papillomavirus (HPV) gene ʹͺ
expression is required for productive infection. The host cell CCCTC-binding factor (CTCF) ʹͻ
functions in genome-wide chromatin organization and gene regulation. We have identified a ͵Ͳ
conserved CTCF binding site in the E2 open reading frame of high-risk HPV types. Using ͵ͳ
organotypic raft cultures of primary human keratinocytes containing high-risk HPV18 ͵ʹ
genomes, we show that CTCF recruitment to this conserved site regulates viral gene ͵͵
expression in differentiating epithelia. Mutation of the CTCF binding site increases the ͵Ͷ
expression of the viral oncoproteins E6 and E7, and promotes host cell proliferation. Loss of ͵ͷ
CTCF binding results in a reduction of a specific alternatively spliced transcript expressed ͵͸
from the early gene region concomitant with an increase in the abundance of unspliced ͵͹
early transcripts. We conclude that high-risk HPV types have evolved to recruit CTCF to the ͵ͺ
early gene region to control the balance and complexity of splicing events that regulate viral ͵ͻ
oncoprotein expression.   ͶͲ
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Importance  Ͷͳ
The establishment and maintenance of human papillomavirus (HPV) infection in Ͷʹ
undifferentiated basal cells of the squamous epithelia requires activation of a subset of viral Ͷ͵
genes, termed early genes. Differentiation of infected cells initiates expression of the late ͶͶ
viral transcripts allowing completion of the virus life cycle. This tightly controlled balance of Ͷͷ
differentiation-dependent viral gene expression allows the virus to stimulate cellular Ͷ͸
proliferation to support viral genome replication with minimal activation of the host immune Ͷ͹
response, thus promoting virus productivity. Alternative splicing of viral mRNAs further Ͷͺ
increases the complexity of viral gene expression. In this study, we show that the essential Ͷͻ
host cell protein CCCTC-binding factor (CTCF), which functions in genome-wide chromatin ͷͲ
organization and gene regulation, is recruited to the HPV genome and plays an essential role ͷͳ
in the regulation of early viral gene expression and transcript processing. These data ͷʹ
highlight a novel virus-host interaction important for HPV pathogenicity.  ͷ͵
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Introduction ͷͶ
Papillomaviruses are a highly diverse family of small DNA tumor viruses that specifically ͷͷ
infect the mucosal and cutaneous epithelium. HPV types that infect the mucosal epithelium ͷ͸
are sub-divided into low-risk and high-risk groups depending on their association with cancer ͷ͹
development (1,2).  ͷͺ
Following infection of cells in the basal layer of epithelium, the viral genome is amplified and ͷͻ
maintained as a low copy episome (estimated to be between 10-200 copies per cell (3)). RNA ͸Ͳ
polymerase-II-dependent transcription of the early proteins is initiated from the early ͸ͳ
promoter located upstream of the E6 ORF (P97 in HPV16 and P105 in HPV18 and 31) within the ͸ʹ
viral upstream regulatory region (URR). This drives expression of the E6 and E7 oncoproteins ͸͵
in the basal cells and stimulates continued cellular proliferation. The E7 gene products target ͸Ͷ
the Retinoblastoma family of proteins pRb/p105 (4) and p107 (5), which control cell cycle ͸ͷ
entry in the basal layer. E7 also targets pRb2/p130 (6), which is highly expressed in the upper ͸͸
layers of the epithelium and prevents cell cycle re-entry (7). To circumvent increased p53 ͸͹
expression and cell cycle arrest arising from E7 expression, high-risk E6 protein binds p53 ͸ͺ
and targets it for degradation (8). By promoting cell cycle re-entry and delaying ͸ͻ
differentiation, E6 and E7 facilitate virus replication in cells that would normally have exited ͹Ͳ
the cell cycle. In the upper epithelial layers, viral genome copy number rises, in part as a ͹ͳ
result of increased production of the viral E1 and E2 proteins (9,10). Increased E2 expression ͹ʹ
is thought to repress E6 and E7 production (11), stimulating cellular differentiation and ͹͵
subsequent activation of the differentiation-dependent late promoter (12). This allows ͹Ͷ
production of transcripts encoding E1^E4, which promotes viral genome amplification (13), ͹ͷ
and the L1 and L2 capsid proteins (14). This intricate balance and control of early and late ͹͸
gene expression is essential for completion of the HPV life cycle.  ͹͹
All HPV transcripts are polycistronic. Alternative splicing and polyadenylation of transcripts ͹ͺ
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further regulate HPV early gene expression and increase the repertoire of expressed ͹ͻ
proteins (14-17). Exactly how splicing of the early transcripts is regulated is not clearly ͺͲ
understood but suboptimal configuration of the 3’ splice sites is thought to allow selection ͺͳ
between alternative splice acceptor sites (14). HPV16 also up-regulates splicing factors in ͺʹ
differentiating epithelium to support late transcript processing (18,19), highlighting the ͺ͵
ability of HPV to manipulate the host environment to control gene expression and co-ͺͶ
ordinate the differentiation-dependent life cycle.  ͺͷ
CCCTC-binding factor (CTCF) is a ubiquitous host architectural protein that binds 10,000 to ͺ͸
50,000 sites within the human genome (20). Dynamic, three-dimensional organization of the ͺ͹
human genome by CTCF controls numerous genomic processes, including transcription, ͺͺ
genetic imprinting, chromatin insulation and gene splicing (21-25). These functions are ͺͻ
coordinated by CTCF through its ability to form long range interactions, bringing together ͻͲ
distant regulatory elements to control gene expression (26), or by forming a roadblock which ͻͳ
slows the transcription machinery and alters co-transcriptional RNA splicing (21). Due to the ͻʹ
highly complex and regulated nature of HPV gene expression and post-transcriptional ͻ͵
processing, we hypothesized that CTCF regulates differentiation-dependent HPV gene ͻͶ
expression. ͻͷ
  ͻ͸
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Materials and Methods ͻ͹
Bioinformatics ͻͺ
The DNA sequences for each HPV type screened are defined in Table 2. Predictions for CTCF ͻͻ
binding site were made with a combination of CTCF binding site databases ͳͲͲ
(http://insulatordb.uthsc.edu/ and ͳͲͳ
http://bsproteomics.essex.ac.uk:8080/bioinformatics/ctcfbind.htm), or using Storm analysis ͳͲʹ
software. The position weight matrices (PWM) utilized by these analysis tools have been ͳͲ͵
previously published (27-29). ͳͲͶ
 ͳͲͷ
Plasmids and antibodies ͳͲ͸
pUC19-HPV6b, pBR322-HPV11 and pBR322-HPV16 were a gift from E-M. de Villiers, DKFZ, ͳͲ͹
Germany. pBR322-HPV31 was a gift from L. Laimins, Northwestern University, USA. pGEMII-ͳͲͺ
HPV18 was a gift from F. Stubenrauch, University of Tübingen, Germany and was used as a ͳͲͻ
template for site directed mutagenesis (QuikChange II XL; Agilent Technologies, USA) to ͳͳͲ
create pGEMII-HPV18-ȴCTCF that contains three conservative nucleotide substitutions ͳͳͳ
(C2993ÎT, G3005ÎA, T3020ÎC) within the E2 coding region. The plasmid pDrive-SP6-His-CTCF ͳͳʹ
was a gift from D. Farrar (University of Essex, UK) and encodes human CTCF protein with a ͳͳ͵
10x histidine tag at the N-terminus. ͳͳͶ
CTCF antibody was purchased from Active Motif (Belgium). FLAG M2 and anti-cytokeratin ͳͳͷ
1/10 8.60 antibodies were purchased from Sigma-Aldrich (UK). Anti-cytokeratin 5 D5/16 B4 ͳͳ͸
was purchased from Boehringer Mannheim Biochemica (Switzerland) and loricrin AF62 from ͳͳ͹
Covance Research Products (UK). BrdU and p130 were purchased from Becton Dickinson ͳͳͺ
(UK). Cyclin B1 H-433, HPV18 E6 (G-7), p53 DO1 and GAPDH were purchased from Santa Cruz ͳͳͻ
Biotechnology (USA).  Phospho-histone H3 (S10) was purchased from Cell Signaling (USA) ͳʹͲ
and HPV18 E7 (8E2) from Abcam (UK). All fluorescent secondary antibodies were purchased ͳʹͳ
from Invitrogen (UK).  Rabbit polyclonal anti-HPV16 E2 antibody was obtained from Prof. ͳʹʹ
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Thierry (Singapore) (9), monoclonal anti E1^E4 1D11 (30) and rabbit polyclonal anti-E1^E4 ͳʹ͵
r424 (31) were used to detect HPV18 E1^E4. ͳʹͶ
 ͳʹͷ
Electrophoretic mobility shift assay (EMSA) ͳʹ͸
DNA fragments were amplified with a forward primer containing an M13-overhang ͳʹ͹
(Sequences available upon request) using Master Mix S (PeqLab, Germany). The products of ͳʹͺ
the first PCR reaction were then amplified in a second PCR reaction using a FAM-labeled ͳʹͻ
M13 forward primer. CTCF protein was produced in an in vitro transcription translation ͳ͵Ͳ
reaction using the TNT® SP6 High-Yield Wheat Germ Protein Expression System (Promega, ͳ͵ͳ
UK).  ͳ͵ʹ
2ʅl of FAM-labeled DNA was incubated with 1ʅl CTCF protein in a 10ʅl reaction containing ͳ͵͵
0.5% NP40, 50 mM KCl and 10mM Tris-HCl pH 7.5, 0.1ʅg/ʅl poly dIdC, 5% Ficol 400, 1mM ͳ͵Ͷ
PMSF and 0.1mM DTT. Samples were incubated at room temperature for 1hr before ͳ͵ͷ
separation on a 4.5% native polyacrylamide gel. FAM fluorescence was imaged at 520nm ͳ͵͸
using a Typhoon FLA7000 (GE Healthcare Life Sciences, UK).  ͳ͵͹
 ͳ͵ͺ
Chromatin immunoprecipitation (ChIP) ͳ͵ͻ
ChIP assays were carried out using the ChIP-IT® Express Enzymatic ChIP Kit (Active Motif) ͳͶͲ
following the manufacturer’s instructions. Cells were fixed in 1% formaldehyde for 3 minutes ͳͶͳ
at room temperature and nuclei released by 40 strokes in a tight dounce homogenizer. DNA ͳͶʹ
was purified using a GenElute PCR Clean-up Kit (Sigma-Aldrich). ChIP efficiency was assessed ͳͶ͵
by qPCR using SensiMixTM SyBr Mastermix (Bioline, London, UK) using an MXPro 3000 ͳͶͶ
(Agilent Technologies). Primer sequences used are available upon request. CT values were ͳͶͷ
calculated at a constant threshold for each experiment and percent of input DNA calculated ͳͶ͸
using the standard curve. ͳͶ͹
 ͳͶͺ
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 ͳͶͻ
Keratinocyte culture, transfection and organotypic raft culture ͳͷͲ
W12 cells containing episomal HPV16 genomes were cultured as previously described (32). ͳͷͳ
The transfection of normal primary foreskin keratinocytes (HFK) from neonatal foreskin ͳͷʹ
epithelia (ethical approval number 06/Q1702/45) was performed in Dr. S. Roberts’ ͳͷ͵
laboratory by Dr. J Parish as previously described (31,33). To eliminate donor-specific effects ͳͷͶ
2 donor lines were used; one produced as described above and one commercially available ͳͷͷ
HFK line (CloneticsTM, Lonza Group Ltd, Basel, Switzerland). Emerging cell colonies were ͳͷ͸
pooled and expanded as previously described (34). Genomes were extracted from each line ͳͷ͹
and sequenced to ensure that the mutations were present in the mutant genome containing ͳͷͺ
lines. Organotypic rafts were prepared (31) and cultured for 14 days in E medium without ͳͷͻ
epidermal growth factor to allow cellular stratification. Sixteen hours prior to harvesting, ͳ͸Ͳ
20ʅM BrdU was added to the growth medium. Rafts were then fixed in 3.7% formaldehyde ͳ͸ͳ
(Sigma-Aldrich) and paraffin embedded prior to sectioning (Propath Ltd, Hereford, UK).  ͳ͸ʹ
 ͳ͸͵
Cell growth assay ͳ͸Ͷ
1 x 105 terminally gamma-irradiated J2-3T3 fibroblasts were seeded to each well of 3x 12 ͳ͸ͷ
well tissue culture microtitre plates and left to adhere. Wells were then seeded with 1x104 ͳ͸͸
HFK lines in triplicate. The growth of cells was measured at day 1, 3 and 5 following removal ͳ͸͹
of J2-3T3 fibroblasts by washing with EDTA and PBS. 500ʅl growth medium and 50ʅl CCK-8 ͳ͸ͺ
reagent (Dojindo Molecular Technologies, Inc) were added to each well and the plate was ͳ͸ͻ
incubated at 37 °C for 2-4 hours. Absorbance was read at 450nm using an iMarkTM ͳ͹Ͳ
microplate reader (Bio-Rad). Wells that contained J2 3T3 fibroblasts but not HFK were used ͳ͹ͳ
as a blank for each plate.  ͳ͹ʹ
 ͳ͹͵
Immunofluorescence ͳ͹Ͷ
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Four ʅm sections of organotypic cultures were placed on poly-lysine-coated slides and ͳ͹ͷ
incubated at 50°C for 30 min. One section from each raft was stained with haematoxylin and ͳ͹͸
eosin for morphological analysis. Antigens were retrieved using an agitated low-temperature ͳ͹͹
method, as previously described (35), following immersion in HistoclearTM (National ͳ͹ͺ
Diagnostics, Yorkshire, UK). Slides were blocked with 20% heat-inactivated goat serum, 0.1% ͳ͹ͻ
BSA in PBS for 1hr at RT. Primary antibodies were incubated on the slides overnight at 4°C. ͳͺͲ
Incubation in secondary antibody was subsequently performed at 37°C for 1 hr. DNA was ͳͺͳ
stained with Hoescht 33342 before mounting in FluoroshieldTM (Sigma-Aldrich). Microscopic ͳͺʹ
analysis was performed in a Nikon E600 epifluorescent microscope and images captured ͳͺ͵
using a Nikon DXM1200F digital camera.  ͳͺͶ
 ͳͺͷ
Chromogenic in situ hybridization  ͳͺ͸
Nuclei positive for HPV DNA amplification in raft sections were detected with a biotin-ͳͺ͹
conjugated high-risk HPV DNA specific probe using Leica Bond-Max technology, as described ͳͺͺ
by the manufacturer (Leica Microsystems, Milton Keynes, UK).  ͳͺͻ
 ͳͻͲ
 ͳͻͳ
Episome copy number determination ͳͻʹ
Southern blotting was performed as described previously (36). For qPCR analysis, relative ͳͻ͵
quantities of HPV18 genome in total DNA, amplified with primers 5’-ͳͻͶ
TTATAGGCGAGCCCAAAAAC-3’ and 5’-CCAATCTCCCCCTTCATCTAT-3’, were normalized ͳͻͷ
against the TLR2 locus at chromosome 4q32 using the Pfaffl comparative CT method (37).  ͳͻ͸
 ͳͻ͹
Transcript analysis ͳͻͺ
RNA was extracted from 14-day-old HFK raft cultures using RNA-STAT 60 (AMS ͳͻͻ
Biotechnology Ltd, UK). 5ʅg of RNA was treated with 1 unit of RQ1 DNase (Promega) for ʹͲͲ
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30min at 37°C, which was subsequently inactivated for 10min. Reverse transcription was ʹͲͳ
performed using Tetro cDNA synthesis kit (Bioline). 2ʅl of cDNA was used for the ʹͲʹ
amplification of HPV transcripts using the primers listed in Table 1. Products were separated ʹͲ͵
by electrophoresis and the relative intensity of each product measured using Image J.   ʹͲͶ
 ʹͲͷ
Statistical analysis ʹͲ͸
A two-tailed, unpaired student’s T-test was used to determine statistical significance.   ʹͲ͹
  ʹͲͺ
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Results ʹͲͻ
Identification of CTCF binding sites in alpha-HPV genomes by bioinformatic analysis. CTCF ʹͳͲ
binding sites in the genomes of low-risk HPV types 6b and 11 and high-risk HPV types 16, 18, ʹͳͳ
31 were predicted using open access databases and Storm analysis software (Table 2). These ʹͳʹ
motif identification tools use a combination PWM previously described (27-29). As ʹͳ͵
hypothesized, all of the HPV types tested were predicted to bind CTCF at multiple sites, ʹͳͶ
although the number of predicted binding sites within different HPV types varied, ranging ʹͳͷ
from six sites in HPV16 to eleven sites in HPV6b and 18. Numerous predicted binding sites ʹͳ͸
clustered within the late gene region of all types studied. An additional site was identified in ʹͳ͹
the E2 open reading frame (ORF) that was conserved in the high-risk but not in the low-risk ʹͳͺ
viral types.  ʹͳͻ
 ʹʹͲ
Verification of CTCF binding sites. To confirm our in silico analysis CTCF binding was ʹʹͳ
assessed in vitro by EMSA. Approximately 200 bp DNA fragments containing the predicted ʹʹʹ
binding motifs were incubated with CTCF protein (Figure 1A) and complexes separated by ʹʹ͵
electrophoresis (Figure 1B). A region of the c-Myc promoter, previously shown to bind CTCF ʹʹͶ
(38), and a fragment of the BPV1 genome not predicted to bind CTCF were included as ʹʹͷ
controls. Fragments were also incubated with wheat germ extract alone and in vitro ʹʹ͸
translated luciferase to control for non-specific binding of proteins. Fragments were tested a ʹʹ͹
minimum of three times and the relative strength of binding in comparison to the c-Myc ʹʹͺ
positive control DNA fragment estimated (Table 2 and Figure 2).  ʹʹͻ
 ʹ͵Ͳ
The binding maps presented in Figure 2 show conservation of CTCF binding between HPV ʹ͵ͳ
types. All types contain a cluster of CTCF binding sites within the late gene region, ranging ʹ͵ʹ
from 2 in HPV6b to 4 binding sites in HPV16. Furthermore, the conservation of one to two ʹ͵͵
CTCF binding sites within (or close to) the E2 ORF of the high-risk HPV types was confirmed. ʹ͵Ͷ
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Binding in this region was not detected in HPV6b or 11 with fragments amplified from this ʹ͵ͷ
region (Table 2). The conservation of CTCF binding sites between HPV types supports our ʹ͵͸
hypothesis that CTCF recruitment is an important virus-host interaction in the HPV life cycle.  ʹ͵͹
 ʹ͵ͺ
CTCF associates with HPV16 and HPV18 genomes. Next, we used HPV16 and HPV18 ʹ͵ͻ
genome-containing cells to ascertain whether CTCF associates with the viral genome in cells. ʹͶͲ
W12 cells, derived from a low-grade cervical squamous epithelial lesion, contain ~100 ʹͶͳ
episomal HPV16 genome copies/cell (39,40) and HPV18 transfected human foreskin ʹͶʹ
keratinocytes (HFKs) contain ~200 episomal HPV18 copies/cell (Figure 5B). CTCF association ʹͶ͵
with the HPV genomes was determined by ChIP followed by qPCR. In both HPV16 and HPV18 ʹͶͶ
genome-containing cells grown in monolayer, we noted a significant enrichment of CTCF ʹͶͷ
binding within the E2 ORF, coinciding with the CTCF binding site conserved in high-risk HPV ʹͶ͸
types but not in low-risk types (Figure 3). In contrast, we failed to detect CTCF binding to the ʹͶ͹
late gene region in either HPV16 or HPV18 genome-containing model systems.  ʹͶͺ
 ʹͶͻ
Loss of CTCF binding to the HPV18 genome does not alter episome establishment or ʹͷͲ
proliferation of primary human foreskin keratinocytes. To assess the biological function of ʹͷͳ
CTCF binding within the E2 ORF, mutations were introduced into the HPV18 genome to ʹͷʹ
prevent CTCF binding (Figure 4A).  Three nucleotide substitutions were introduced into the ʹͷ͵
predicted binding site that did not alter the amino acid coding sequence of E2 (∆CTCF ʹͷͶ
HPV18). It should be noted that CTCF also has the potential to bind to the complementary ʹͷͷ
DNA strand within this region (at the sequence 5’ CACCACCTGGTGGT 3’) although the ʹͷ͸
mutations introduced would also affect binding at this site. We observed a near complete ʹͷ͹
loss of CTCF binding to the ∆CTCF HPV18 sequence in EMSA confirming that the mutations ʹͷͺ
prevented CTCF binding (Figure 4B). HFKs were transfected with recircularized wild type ʹͷͻ
(WT) or ∆CTCF HPV18 genomes and immortalized lines established. To account for donor-ʹ͸Ͳ
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specific effects, cells from two independent donors were transfected and all downstream ʹ͸ͳ
analyses were performed on both lines. No significant differences in cellular morphology ʹ͸ʹ
(data not shown) or growth were observed between WT and ∆CTCF lines (Figure 5A). The ʹ͸͵
physical state of the HPV genomes was determined by Southern blotting and qPCR. Both WT ʹ͸Ͷ
and ∆CTCF HPV18 lines were shown to contain episomal HPV genomes at a similar copy ʹ͸ͷ
number of approximately 200 copies/cell (Figure 5B and C). Importantly, we demonstrated a ʹ͸͸
10-fold reduction in CTCF binding to ∆CTCF HPV18 genomes compared to WT (Figure 5D). ʹ͸͹
 ʹ͸ͺ
Loss of CTCF binding induces a hyperproliferative phenotype in organotypic culture. To ʹ͸ͻ
assess the biological function of CTCF recruitment to the HPV18 genome in differentiating ʹ͹Ͳ
epithelium, WT and ∆CTCF HPV18 HFK lines were grown in organotypic raft culture. ʹ͹ͳ
Formaldehyde fixed ‘rafts’ were paraffin embedded and sectioned. Sections were stained ʹ͹ʹ
with hematoxylin and eosin to assess morphology (Figure 6A). As previously described, the ʹ͹͵
WT HPV18 genome containing rafts were increased in thickness and mitotic cells were ʹ͹Ͷ
visible in the lower and upper suprabasal layers of the rafts in comparison to rafts derived ʹ͹ͷ
from HFKs that did not contain HPV18 genomes (13). This phenotype was enhanced in ʹ͹͸
∆CTCF HPV18 rafts, which were consistently thicker indicating increased cellular ʹ͹͹
proliferation. Alongside these experiments, viral genome amplification was assessed by ʹ͹ͺ
chromogenic in situ hybridization (C-ISH). No consistent differences were observed in the ʹ͹ͻ
number of cells with amplified HPV genomes between WT and ∆CTCF HPV18 rafts, ʹͺͲ
demonstrating that CTCF recruitment has a minimal role in viral genome amplification ʹͺͳ
(Figure 6A and B).  ʹͺʹ
 ʹͺ͵
Increased S phase and G2 entry is caused by loss of CTCF binding. The increase in ʹͺͶ
hyperproliferation in ∆CTCF HPV18 rafts could either be explained by delayed epithelial ʹͺͷ
differentiation, or by increased S phase entry. To assess molecular differentiation, raft ʹͺ͸
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sections were stained for markers of undifferentiated keratinocytes (keratin 5), early ʹͺ͹
differentiation (keratin 1) and late differentiation (loricrin) alongside E1^E4, a marker of the ʹͺͺ
productive phase of the HPV life cycle (Figure 6C). Expression patterns of keratin 5, keratin 1 ʹͺͻ
and loricrin were similar between WT and ∆CTCF HPV18 organotypic cultures with keratin 5 ʹͻͲ
confined to the basal and parabasal layers with some non-specific staining visible in the ʹͻͳ
cornified layer of the epithelium; keratin 1 and loricrin expressed in the suprabasal and ʹͻʹ
upper layers, respectively. However, keratin 1 and loricrin staining highlighted differences in ʹͻ͵
the morphology of cells in the suprabasal and upper layers of the epithelium; rather than a ʹͻͶ
flattening of these cells in the upper layers, as can be seen in the WT HPV18 sections, the ʹͻͷ
cells appeared to maintain a rounded morphology. This difference in morphology is also ʹͻ͸
visible in the hematoxylin and eosin stained sections shown in Figure 6A.  ʹͻ͹
BrdU incorporation was used to assess cell cycle entry and cellular DNA replication. BrdU ʹͻͺ
positive cells were confined to the basal layer in rafts derived from untransfected donor ʹͻͻ
keratinocytes (Figure 7A). Increased S phase entry was observed in the basal and suprabasal ͵ͲͲ
layers of the WT HPV18 rafts, as previously reported (36). In contrast, ∆CTCF HPV18 rafts ͵Ͳͳ
displayed a significant decrease in S phase entry in the basal layer as compared to WT. A ͵Ͳʹ
decrease in the percentage of BrdU positive cells was observed in the lower suprabasal ͵Ͳ͵
layers of ∆CTCF HPV18 rafts compared to WT, although this did not reach significance. In ͵ͲͶ
contrast a significant increase in the percentage of BrdU positive cells was observed in the ͵Ͳͷ
upper suprabasal layers of the ∆CTCF HPV18 rafts (Figure 7B).  ͵Ͳ͸
Raft sections were also stained for cyclin B1 and phospho-histone H3 (Ser10) (P-H3) as ͵Ͳ͹
markers of G2 and mitotic entry, respectively (Figure 7C and E). In agreement with the BrdU ͵Ͳͺ
incorporation analysis (Figure 7A and B), a decrease in cells positive for cytoplasmic cyclin B1 ͵Ͳͻ
was observed in the basal layer of ∆CTCF HPV18 lines compared to WT. No significant ͵ͳͲ
difference was observed in the lower suprabasal compartment but an increase in ͵ͳͳ
cytoplasmic cyclin B1 in the upper suprabasal layers was noted (Figure 7C and D). In ͵ͳʹ
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contrast, there was no difference in the number of cells positive for P-H3 in WT and ∆CTCF ͵ͳ͵
HPV18 structures (Figure 7E and F). Taken together, these data indicate that there is an ͵ͳͶ
increase in cell cycle entry with a corresponding increase in S and G2 phases in the upper ͵ͳͷ
layers of the epithelium of ∆CTCF HPV18 cells. The cells appear to arrest at G2 phase as an ͵ͳ͸
increase in mitotic entry is not observed. These data provide evidence that loss of CTCF ͵ͳ͹
binding within HPV18 E2 ORF leads to a delay in cell cycle exit and an enhanced ͵ͳͺ
hyperproliferative phenotype.  ͵ͳͻ
 ͵ʹͲ
CTCF binding within the E2 ORF controls the expression of viral oncoproteins E6 and E7. ͵ʹͳ
The increased cell cycle entry and hyperproliferation observed in the organotypic raft ͵ʹʹ
cultures derived from HFK lines maintaining ∆CTCF HPV18 genomes could be due to an ͵ʹ͵
increase in the expression of E6 and E7 viral oncoproteins. Detection of these proteins by ͵ʹͶ
immunostaining is not currently possible, therefore raft sections were stained with ͵ʹͷ
surrogate markers; p53 as a marker for E6 expression and pRb family member p130 for E7 ͵ʹ͸
expression (8,41). Cells stained positive for p53 in WT HPV18 raft sections were apparent ͵ʹ͹
throughout the epithelia as previously reported (42), albeit at a noticeably decreased level ͵ʹͺ
than rafts derived from untransfected HFKs (Figure 8A). In contrast, p53 positive cells were ͵ʹͻ
undetectable in rafts derived from ∆CTCF HPV18 lines (Figure 8A and B). This observation is ͵͵Ͳ
consistent with an increase in E6 protein levels in ∆CTCF HPV18 compared to WT, resulting ͵͵ͳ
in a decrease in detectable p53 protein. Similarly, immunostaining with p130-specific ͵͵ʹ
antibodies revealed significant differences between WT and ∆CTCF HPV18 rafts (Figure 8C ͵͵͵
and D). In wild type HPV18 rafts, p130 positive cells were confined to the upper layers, as ͵͵Ͷ
previously shown (42), and in contrast to HPV negative HFK raft sections where cells stained ͵͵ͷ
positive for p130 in the parabasal, lower and upper suprabasal layers. However, ͵͵͸
immunostaining of p130 in the ∆CTCF HPV18 raft sections revealed an almost complete loss ͵͵͹
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of p130 positive cells in the upper layers, suggesting increased and prolonged expression of ͵͵ͺ
E7 protein in the ∆CTCF HPV18 rafts compared to WT.  ͵͵ͻ
Since p53 and p130 expression only provide an indication of E6 and E7 activity, we also ͵ͶͲ
quantified expression of early transcripts that have the potential to encode E6 and E7 by ͵Ͷͳ
reverse transcriptase-PCR (RT-PCR).  As expected, the relative abundance of unspliced E6E7 ͵Ͷʹ
transcripts in ∆CTCF HPV18 raft cultures was significantly increased compared to WT (Figure ͵Ͷ͵
9A and B). E6E7 transcript levels were also measured by qPCR using the same primer set as ͵ͶͶ
described above and compared to the human RPLPO gene (Life Technologies). A ratio of ͵Ͷͷ
E6E7 transcript to RPLPO transcript in HPV18 wild type and ∆CTCF rafts was calculated using ͵Ͷ͸
the Livak 2∆∆CT method. Donor 1 was shown to have a 21.19 fold increase (±10.48 s.e.) and ͵Ͷ͹
donor 2 had a 44.08 fold increase (±26.95 s.e.) in E6E7 transcript in the HPV18 ∆CTCF rafts ͵Ͷͺ
compared to wild type. In addition, western blot analysis of protein extracts from raft ͵Ͷͻ
cultures harvested at day 14 demonstrated a clear increase in E6 and E7 protein levels ͵ͷͲ
(Figure 9C), which was consistent in both donor lines.  ͵ͷͳ
The increase in E6E7 unspliced transcript could be due to an increase in the activity of the ͵ͷʹ
early promoter. HPV encoded E2 protein is known to repress the activity of this promoter ͵ͷ͵
and changes in E2 expression could affect early promoter activity (43-45). To determine ͵ͷͶ
whether the expression level of E2 protein was affected by the mutations introduced into ͵ͷͷ
the E2 ORF in the ∆CTCF HPV18 genome, E2 protein levels in raft lysates were detected by ͵ͷ͸
western blotting and no changes were observed (Figure 9C). Furthermore, immunostaining ͵ͷ͹
of sections showed E2 staining in the intermediate and upper layers of the WT raft cultures, ͵ͷͺ
with obvious cytoplasmic and nuclear localization. As previously described, E2 staining was ͵ͷͻ
not detected in the basal and lower suprabasal cells, presumably because E2 protein levels ͵͸Ͳ
are below the level of detection (9). No staining was detected in the HPV negative HFK raft ͵͸ͳ
control demonstrating specificity of the antibody. An equal intensity of E2-specific signal was ͵͸ʹ
observed in the upper layers of wild type and ∆CTCF HPV18 rafts, although a delay in E2 ͵͸͵
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expression was consistently observed in ∆CTCF HPV18 rafts compared to WT. This is ͵͸Ͷ
presumably due to an expansion of the E2 negative mid-layers of the epithelium caused by ͵͸ͷ
increased E6 and E7 expression (Figure 9D). Together, these data confirm that steady state ͵͸͸
E2 levels in the raft cultures were not affected by the mutations introduced into the HPV18 ͵͸͹
genome. Collectively, these data demonstrate that CTCF recruitment to the conserved site ͵͸ͺ
within the E2 ORF is important in the regulation of viral oncoprotein expression in the ͵͸ͻ
differentiation-dependent life cycle through a mechanism that does not involve aberrant E2 ͵͹Ͳ
protein expression.  ͵͹ͳ
 ͵͹ʹ
CTCF controls RNA splicing of early viral transcripts. A diverse range of early transcripts is ͵͹͵
expressed from the HPV genome as a result of numerous alternative splicing events (14,15). ͵͹Ͷ
Alterations in the splicing events that are important in early gene expression in HPV ͵͹ͷ
infections could have a dramatic effect on the expression of early proteins and their ͵͹͸
truncated forms (E6*I, E6*II and E6*III (14)). Given its previously described role in the ͵͹͹
control of RNA splicing (21), CTCF binding to the E2 ORF could affect splicing of the early ͵͹ͺ
transcripts and viral oncoprotein expression. To test this hypothesis, RNA was extracted ͵͹ͻ
from raft cultures harvested at day 14 and early transcripts amplified by RT-PCR with primer ͵ͺͲ
pairs that have been previously designed to identify the specific splicing events that occur ͵ͺͳ
within the early region of the HPV18 genome (14,15). Amplification with a 5’ primer that ͵ͺʹ
anneals at nucleotide 121, upstream of the first splice donor site at nucleotide 233, and 3’ ͵ͺ͵
primer that anneals at nucleotide 3517, downstream of the five splice acceptor sites in the ͵ͺͶ
early region of HPV18 at nucleotides 416, 2779, 3434, 3465 and 3506 (14,15) was used to ͵ͺͷ
detect any major splicing events that occur in the early region of the HPV18 genome. ͵ͺ͸
Amplification of RNA from WT HPV18 rafts resulted in two major products with some minor ͵ͺ͹
products visible (Figure 10A). As previously described (14), the two major products of 708 ͵ͺͺ
and 195 base pairs were identified by sequencing and shown to be spliced at 233^416 and ͵ͺͻ
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929^3434, and 233^3434, respectively (Figure 10B). Both of these products were ͵ͻͲ
consistently expressed in five raft cultures from each individual donor line of WT HPV18 ͵ͻͳ
HFKs. Of note, the 195 base pair product, spliced between nucleotide 233 and 3434, was ͵ͻʹ
significantly reduced and in some cases absent in the ∆CTCF HPV18 raft cultures (Figure 10A ͵ͻ͵
and C). This is in contrast to the increase in unspliced transcript in the ∆CTCF HPV18 rafts ͵ͻͶ
(Figure 9A and B). A significant reduction in production of the short mRNA species ͵ͻͷ
(233^3434 spliced product) could therefore result in the observed increase in unspliced E6E7 ͵ͻ͸
transcripts.  Further analysis of viral transcripts revealed that splicing events at nucleotides ͵ͻ͹
233^416 and 929^3434 were not altered by loss of CTCF binding (Table 3). These ͵ͻͺ
experiments demonstrate that loss of CTCF binding at position 2989 within the HPV18 ͵ͻͻ
genome results in a significant alteration in splice site usage, with specific loss of 233^3434 ͶͲͲ
spliced products in the early transcripts expressed.   ͶͲͳ
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Discussion ͶͲʹ
This study aimed to identify CTCF binding sites within the genomes of various HPV types and ͶͲ͵
to understand the function of CTCF in the virus life cycle. In silico predictions were used to ͶͲͶ
identify potential CTCF binding sites, a high frequency of which bound CTCF in vitro. The ͶͲͷ
relative position of many of the CTCF binding sites is conserved. A cluster of CTCF binding ͶͲ͸
sites was identified in the late gene region of all of the HPV types tested and binding within ͶͲ͹
the E2 ORF appears to be conserved in the high-risk types, indicating that recruitment of ͶͲͺ
CTCF to this region is related to the ability of the virus to induce cellular transformation. This ͶͲͻ
suggests that the recruitment of CTCF to these regions was an early evolutionary event and ͶͳͲ
that CTCF is important for the virus life cycle. Furthermore, the frequency of CTCF binding Ͷͳͳ
sites within the genomes of the HPV types analysed in this study show an enrichment of Ͷͳʹ
sites compared to the frequency of binding sites within the human genome (20).  Ͷͳ͵
In contrast to the binding of CTCF within the E2 ORF in HPV16 and 18, CTCF recruitment ͶͳͶ
within the late gene region was not detected in genome-containing cells. The conservation Ͷͳͷ
of the CTCF binding site cluster in the late gene region suggests that recruitment of CTCF to Ͷͳ͸
the late region is important for a defined point in the HPV life cycle. During submission of Ͷͳ͹
this manuscript, we became aware of a study by Metha et al in which CTCF was shown to Ͷͳͺ
associate with the sites within the L2 gene of the late gene region of HPV31. Loss of CTCF Ͷͳͻ
binding to the HPV31 L2 gene appears to prevent viral genome amplification (Metha K, ͶʹͲ
Gunasekharan V, Satsuka A, Laimins L, submitted for publication). However, our data show Ͷʹͳ
that CTCF does not bind within the late gene region in HPV16 and HPV18 in cells grown in Ͷʹʹ
monolayer culture. It is possible that CTCF recruitment to this region is promoted by cellular Ͷʹ͵
differentiation and this is important for capsid protein expression or viral genome ͶʹͶ
amplification. Differentiation-induced loss of CpG methylation in the late region of episomal Ͷʹͷ
HPV16 genomes has been reported (46). CpG methylation can negatively regulate CTCF Ͷʹ͸
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binding (47), making this method of regulation of CTCF recruitment to the late gene region Ͷʹ͹
of the HPV genome in differentiating epithelium a plausible hypothesis.  Ͷʹͺ
Several host cell proteins are recruited to the HPV genome to regulate transcriptional Ͷʹͻ
control. The binding of host cell transcription factors to sequences within the URR to control Ͷ͵Ͳ
early gene transcription has been well characterized. Transcriptional regulators such AP1 Ͷ͵ͳ
(48), SP1 (49), TFIID (50), TBP (51), NF1 and Oct-1 (52) have defined binding sites within the Ͷ͵ʹ
URR of all HPV types analyzed.  Many other transcriptional regulators are recruited by Ͷ͵͵
association with the E2 protein including Brd4 (53), TaxBP1 (54), p300 and CBP (55). In Ͷ͵Ͷ
contrast, very few host or viral proteins have been shown to specifically bind to the HPV Ͷ͵ͷ
genome outside of the URR, although evidence of C/EBPβ, Oct-1 and YY1 binding to Ͷ͵͸
sequences upstream of the late promoter within the E7 ORF in HPV18 has been reported Ͷ͵͹
(56-58). The recruitment of CTCF to a binding site that exists within the E2 ORF is to our Ͷ͵ͺ
knowledge the first description of a cellular factor recruited to a specific binding site outside Ͷ͵ͻ
of the URR or late promoter regions to control viral gene expression.  ͶͶͲ
Mutation of the CTCF binding site within the E2 ORF of HPV18 has highlighted an important ͶͶͳ
function of CTCF in the HPV life cycle. Growth of cells in organotypic raft culture was ͶͶʹ
affected by abrogation of CTCF binding and we noted a significant increase in cellular ͶͶ͵
proliferation coupled with enhanced E6 and E7 protein expression. These data provide ͶͶͶ
evidence that loss of CTCF binding within the E2 ORF enhances E6 and E7 expression in ͶͶͷ
differentiating cells, prolonging the proliferative potential of cells in the mid- and upper- ͶͶ͸
layers of the stratified epithelium. It is interesting to note that although we observed an ͶͶ͹
increase in cell cycle entry in the ∆CTCF HPV18 raft cultures, we did not observe an increase ͶͶͺ
in mitotic entry. One possible explanation for this is that the raft cultures were harvested at ͶͶͻ
14 days when the epithelia were fully differentiated. It is possible that an increase in mitosis ͶͷͲ
occurs as the epithelium is developing and that in a fully differentiated epithelium, the cells Ͷͷͳ
are more likely to arrest in G2 than progress through mitosis. Importantly, there were no Ͷͷʹ
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discernable effects on the overall expression of E2, although expansion of the mid-layers of Ͷͷ͵
the epithelium resulted in an apparent delay in E2 expression. In addition, viral genome ͶͷͶ
replication and amplification were unaffected, suggesting that E1 protein levels were Ͷͷͷ
unaffected. This suggests that HPV18 and perhaps other oncogenic HPV types have evolved Ͷͷ͸
to bind CTCF in this region to regulate balanced and controlled E6 and E7 expression in the Ͷͷ͹
context of a productive infection. Interestingly, CTCF does not appear to bind to the site Ͷͷͺ
within the E2 ORF in integrated sequences in HeLa cells (59), even though three copies of the Ͷͷͻ
binding site exist (60). It is possible that CpG methylation prevents CTCF binding to this site Ͷ͸Ͳ
in HeLa cells, as previously reported (47,61) and it is tempting to speculate that the apparent Ͷ͸ͳ
loss of CTCF binding in integrated HPV18 genomes in HeLa cells contributes to the high E6 Ͷ͸ʹ
and E7 expression in these cells.  Ͷ͸͵
It should be noted that CTCF binding sites have been identified within the genomes of large Ͷ͸Ͷ
DNA viruses such as Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus Ͷ͸ͷ
(KSHV). Mutation of sites to prevent CTCF binding has demonstrated that CTCF determines Ͷ͸͸
latency in these viruses by blocking epigenetic silencing of latency-associated promoter Ͷ͸͹
elements and mediating long-range interactions within the viral genome (62-68). This, in Ͷ͸ͺ
part, is thought to be through CTCF-dependent regulation of nucleosome organization and Ͷ͸ͻ
control of RNA polymerase-II recruitment to the latency control region (69,70).  Whether Ͷ͹Ͳ
CTCF binding within the E2 ORF of the HPV genome directly controls E6E7 transcript Ͷ͹ͳ
production through similar mechanisms is currently being explored.  Ͷ͹ʹ
CTCF binding within the host genome controls co-transcriptional alternative splicing events Ͷ͹͵
by creating a roadblock to processing RNA polymerase-II and thereby promoting inclusion of Ͷ͹Ͷ
weak upstream exons (21). We therefore analyzed splicing events that occur in the HPV Ͷ͹ͷ
early transcripts in differentiating epithelium and demonstrated a significant increase in the Ͷ͹͸
unspliced early transcript that encodes the E6 and E7 oncoproteins. In addition, the Ͷ͹͹
transcript spliced directly at 233^3434 was markedly reduced in ∆CTCF HPV18 rafts, while Ͷ͹ͺ
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the abundance of all other spliced products was unchanged. The transcript spliced at Ͷ͹ͻ
233^3434 could be used as a template for translation of E6*II and E5 (14). Multiple ͶͺͲ
transcripts that are abundantly and equally expressed in our WT and ∆CTCF rafts potentially Ͷͺͳ
encode E5 protein, making it unlikely that E5 expression is affected by loss of CTCF binding. Ͷͺʹ
Whether loss of E6*II expression contributes to the phenotype observed in our mutant Ͷͺ͵
HPV18 HFK rafts remains to be determined.  ͶͺͶ
Our data suggest that CTCF recruitment to the E2 ORF binding site is a control mechanism Ͷͺͷ
for the expression of unspliced and alternatively spliced early transcripts in the HPV life Ͷͺ͸
cycle. It is interesting that the current model of CTCF-mediated splicing regulation predicts Ͷͺ͹
that DNA-bound CTCF pauses RNA polymerase-II progression and promotes the inclusion of Ͷͺͺ
weak upstream exons by allowing the splicing machinery more time to process the nascent Ͷͺͻ
RNA strand (21). Our data support a role for CTCF in directing splicing events, but suggests ͶͻͲ
that the function of CTCF in this process is likely to be more complex than the current model Ͷͻͳ
predicts. In our physiologically relevant model system, loss of CTCF binding results in both Ͷͻʹ
increased levels of unspliced transcripts and a complex alteration of splice site usage Ͷͻ͵
upstream of the CTCF binding site. Further study of CTCF in the regulation of RNA processing ͶͻͶ
will likely highlight novel functions of CTCF in gene expression regulation.  Ͷͻͷ
  Ͷͻ͸
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Figure Legends ͹ͲͲ
Figure 1: In vitro analysis of the association of CTCF with HPV genomes. (A) Western blot ͹Ͳͳ
analysis of in vitro translated CTCF protein. Lysate from ID13 (mouse) cells known to express ͹Ͳʹ
CTCF was loaded as a positive control. A band running at approximately 140 kDa was ͹Ͳ͵
present in the ID13 cell lysate and a slightly smaller band was present in the in vitro ͹ͲͶ
translated CTCF reaction. Human CTCF is an 82 kDa protein but runs at approximately ͹Ͳͷ
130kDa on SDS PAGE (71), whereas the mouse homologue is slightly larger. (B) An example ͹Ͳ͸
of an EMSA of CTCF binding to predicted BPV DNA fragments. DNA fragments were ͹Ͳ͹
amplified and labeled with FAM by PCR. Fragments were mixed with binding buffer only ͹Ͳͺ
(DNA), in vitro translated luciferase protein (-) or in vitro translated CTCF protein (+), and ͹Ͳͻ
protein-DNA complexes separated on a native acrylamide gel. Free DNA is indicated at the ͹ͳͲ
bottom of the gel and Protein-DNA complexes near the top. Each fragment was tested a ͹ͳͳ
minimum of three times and the combined results are shown in Table 2. Fragments from ͹ͳʹ
the c-Myc locus (positive control), a region of the BPV-1 genome that is known not to bind ͹ͳ͵
CTCF (negative control) and fragment 11 from HPV18 and fragments 1 and 10 from HPV31 ͹ͳͶ
are shown in the representative EMSA shown. 18_11 and 31_10 bound CTCF with medium ͹ͳͷ
strength (50-75% binding compared to the c-Myc positive control) and 31_1 did not bind ͹ͳ͸
CTCF in vitro.  ͹ͳ͹
 ͹ͳͺ
Figure 2: Summary of in silico predicted CTCF binding sites and in vitro analysis. Graphical ͹ͳͻ
representations of the HPV16, 18, 31, 11 and 6b genomes are shown. ORFs are indicated on ͹ʹͲ
each genome (light grey). Predicted CTCF binding sites are represented by the black bars. ͹ʹͳ
The hashed bars on the periphery of each genome highlight fragments tested by EMSA and ͹ʹʹ
the dark grey bars on each genome indicate those fragments that bound CTCF in vitro.  ͹ʹ͵
 ͹ʹͶ
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Figure 3: Association of CTCF with HPV genomes. Chromatin extracted from (A) HPV16 ͹ʹͷ
positive W12 cells and (B) HPV18 positive HFKs was immunoprecipitated with control ͹ʹ͸
antibody (rabbit IgG for W12 and FLAG M2 antibody for HPV18 HFKs) or CTCF specific ͹ʹ͹
antibody. Co-precipitating DNA was analyzed by qPCR. The x-axes indicate the position in ͹ʹͺ
the HPV genome amplified and each data point represents the central point in each ͹ʹͻ
amplicon. A graphical representation of the HPV genome is shown above each data set, ͹͵Ͳ
which has been linearized for ease of presentation. The CTCF binding sites verified by EMSA ͹͵ͳ
(Figure 1 and Table 2) are indicated (dark grey ovals). Binding efficiency was normalized to ͹͵ʹ
negative control antibody using the ∆∆CT method. The data represent the mean and ͹͵͵
standard error of three independent repeats.  ͹͵Ͷ
 ͹͵ͷ
Figure 4: Mutation of the CTCF binding site at position 2989 in HPV18. (A) Wild type HPV18 ͹͵͸
sequence between nucleotides 2976 and 3035 showing the primary CTCF binding site ͹͵͹
starting at nucleotide 2989 and the secondary binding site in lowercase. The amino acid ͹͵ͺ
sequence of E2 protein encoded within this region is shown below the DNA sequence. The 3 ͹͵ͻ
conservative nucleotide substitutions created in the mutated ∆CTCF HPV18 genome ͹ͶͲ
(CÎT2993, GÎA3002 and TÎC3020) are indicated (*). (B) Abrogation of CTCF binding was ͹Ͷͳ
assessed by EMSA. The CTCF binding region of the c-Myc locus (positive control) and a ͹Ͷʹ
region of the BPV-1 genome that does not contain CTCF binding sites (negative control), the ͹Ͷ͵
CTCF binding region in the E2 ORF in wild type and ∆CTCF mutant genomes were amplified ͹ͶͶ
and FAM-labeled by PCR. DNA fragments were mixed with binding buffer (DNA) alone or ͹Ͷͷ
with in vitro translated luciferase (-) or CTCF (+) and complexes separated on a native ͹Ͷ͸
acrylamide gel. In agreement with data presented in Table 2, CTCF bound strongly to the ͹Ͷ͹
wild type HPV18 (18_3) fragment as compared to the positive control, however binding of ͹Ͷͺ
CTCF to the ∆CTCF mutant fragment was severely disrupted.   ͹Ͷͻ
 ͹ͷͲ
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Figure 5: Creation of HPV18 wild type and ∆CTCF mutant human foreskin keratinocyte ͹ͷͳ
lines. HFKs established from two independent donors were transfected with WT or ∆CTCF ͹ͷʹ
HPV18 genomes. (A) Analysis of growth kinetics using a CCK-8 metabolic assay. Cells were ͹ͷ͵
seeded at equal density at day 0 and growth of each line was measured at days 1, 3, 5 and ͹ͷͶ
7. The data show the mean and standard error of two independent experiments performed ͹ͷͷ
in triplicate. (B) HPV18 genome copy number was determined by qPCR analysis of DpnI ͹ͷ͸
digested DNA extracted from each line using the Pfaffl comparative CT method and ͹ͷ͹
normalized against TLR2 locus (37). Data show the mean and standard error of three ͹ͷͺ
independent repeats (donor 1, p = 0.9; donor 2, p = 0.2). (C) HPV18 genome status was ͹ͷͻ
determined by Southern blot from extracted DNA from donor 1 (1) and donor 2 (2) ͹͸Ͳ
transfected with either wild type (WT) or ∆CTCF mutant (∆C) HPV18 genomes (OC, open ͹͸ͳ
circle; L, linear; SC, supercoiled). DNA was linearized with EcoRI, producing a single band of ͹͸ʹ
similar intensity running at approximately 8kbps, demonstrating maintenance of viral ͹͸͵
episomes at a similar a copy number in each line. Digestion with BglII shows minimal ͹͸Ͷ
multimeric/integrated HPV genomes in all lines. (D) Abrogation of CTCF binding by mutation ͹͸ͷ
of the CTCF binding site was determined by ChIP. Chromatin was either immunoprecipitated ͹͸͸
with FLAG (negative control) or CTCF antibody and the percentage of bound HPV18 genome ͹͸͹
was determined by qPCR with primers that flank the CTCF binding site at position 2989. A ͹͸ͺ
significant decrease in CTCF binding was observed in ∆CTCF HPV18 as compared to wild ͹͸ͻ
type (** p = 0.01). The data shown represent the mean and standard error of two ͹͹Ͳ
independent repeats performed in duplicate (Donor 1; Donor 2 showed a similar decrease ͹͹ͳ
in CTCF binding).  ͹͹ʹ
 ͹͹͵
Figure 6: Morphology and differentiation of HPV18 ∆CTCF organotypic raft cultures. (A) ͹͹Ͷ
Organotypic raft cultures of HFK, WT HPV18 and ∆CTCF HPV18 lines were fixed at day 14 ͹͹ͷ
and sections were stained with haematoxylin and eosin to assess morphology (upper ͹͹͸
panels). Sections were stained by chromogenic in situ hybridisation (C-ISH) to qualitatively ͹͹͹
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assess viral genome amplification (lower panels). Brown nuclear staining is present in cells ͹͹ͺ
with amplified HPV18 genomes. Scale bar = 10 ʅm. (B) The number of cells positive for C-ISH ͹͹ͻ
in wild type and ∆CTCF HPV18 sections was counted in 10 fields of vision from sections of ͹ͺͲ
three independent raft cultures from each line (n = 30). The data are shown as the mean ͹ͺͳ
and standard error. (C) Sections were stained with antibodies specific for keratin 5 (green, ͹ͺʹ
upper panel), keratin 1 (green, middle panel) or loricrin (red, lower panel). Sections were ͹ͺ͵
counterstained with Hoechst to highlight the nuclei (blue) and E1^E4 antibody to highlight ͹ͺͶ
productive areas of each section (red in upper and middle panels (rabbit antibody r424), ͹ͺͷ
green in the lower panel (mouse antibody 1D11)). Scale bar = 10 ʅm.  ͹ͺ͸
 ͹ͺ͹
Figure 7: Cell cycle entry in wild type and ∆CTCF mutant HPV18 genome containing ͹ͺͺ
organotypic raft sections. Sections were stained with (A) anti-BrdU (green), (C) cyclin B1 ͹ͺͻ
(red) and (E) phospho-histone H3 (Green). DNA stained with Hoescht to highlight the nuclei ͹ͻͲ
(blue). Representative sections of WT and ∆CTCF HPV18 genome containing HFK rafts are ͹ͻͳ
shown. The white arrows indicate the basal layer, and the lower suprabasal/upper ͹ͻʹ
suprabasal boundary is highlighted with a dashed line. Scale bar = 10 ʅm. The percentage of ͹ͻ͵
cells stained positive for (B) nuclear BrdU, (D) cytoplasmic cyclin B1 and (F) Phospho-histone ͹ͻͶ
H3 in the basal, lower suprabasal (parabasal and lower spinous) and upper suprabasal ͹ͻͷ
(upper spinous and granular) layers of 15 fields of view of 3 independent rafts (n = 45) from ͹ͻ͸
each donor was determined. The data represent the mean and standard error. (B) A ͹ͻ͹
significant reduction in BrdU incorporation is observed in the basal layer of ∆CTCF HPV18 ͹ͻͺ
lines (*** p = 0.002), a small reduction is observed in the lower suprabasal compartment ͹ͻͻ
that did not reach significance (p = 0.07) and a significant increase in BrdU incorporation is ͺͲͲ
observed in the upper suprabasal layers of the ∆CTCF HPV18 rafts compared to wild type ͺͲͳ
(*** p = 0.0002). (D) A significant reduction in cyclin B1 positive cells is observed in the basal ͺͲʹ
layer of ∆CTCF HPV18 lines (* p = 0.04), no difference is observed in the suprabasal ͺͲ͵
compartment and a significant increase in cyclin B1 positive cells is observed in the upper ͺͲͶ
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layers of the ∆CTCF HPV18 rafts compared to wild type (*** p = 0.00006). (F) No significant ͺͲͷ
differences in P-H3 positive cells were observed. ͺͲ͸
 ͺͲ͹
Figure 8: Analysis of p53 and p130 degradation in wild type and ∆CTCF HPV18 organotypic ͺͲͺ
raft sections. (A) Sections were stained with p53-specific antibody (green) and DNA stained ͺͲͻ
with Hoescht (blue). The white arrows indicate the basal layer, and the lower ͺͳͲ
suprabasal/upper suprabasal boundary is highlighted with a dashed line. Scale bar = 5 ʅm. ͺͳͳ
(B) The percentage of cells positive for nuclear p53 staining in the basal, lower suprabasal ͺͳʹ
(parabasal and lower spinous) and upper suprabasal (upper spinous and granular) layers of ͺͳ͵
15 fields of view of 3 independent rafts (n = 45) from each donor was determined. The data ͺͳͶ
represent the mean and standard error. A significant reduction in p53 positive cells is ͺͳͷ
observed in all layers of rafts derived from the ∆CTCF HPV18 lines (*** p < 0.0005). (C) ͺͳ͸
Sections were stained with p130-specific antibody (green) and DNA stained with Hoescht ͺͳ͹
(blue). The white arrows indicate the basal layer, and the lower suprabasal/upper ͺͳͺ
suprabasal boundary is highlighted with a dashed line. Scale bar = 5 ʅm. (D) The percentage ͺͳͻ
of cells positive for nuclear p130 staining in the basal, lower suprabasal (parabasal and ͺʹͲ
lower spinous) and upper suprabasal (upper spinous and granular) layers of 15 fields of view ͺʹͳ
of 3 independent rafts (n = 45) from each donor was determined. The data represent the ͺʹʹ
mean and standard error. A significant reduction in p130 positive cells is observed in all ͺʹ͵
layers of rafts derived from the ∆CTCF HPV18 lines (*** p < 0.001). ͺʹͶ
 ͺʹͷ
Figure 9: Analysis of unspliced E6E7 transcript and protein expression in organotypic raft ͺʹ͸
culture. RNA extracted from 14-day-old raft cultures was converted to cDNA and amplified ͺʹ͹
between nucleotide 121 and 295. The products of this PCR reaction are unspliced early ͺʹͺ
transcripts(14). Amplification of GADPH from the same samples is shown as a loading ͺʹͻ
control. (A) Products were separated by electrophoresis and (B) quantified by densitometry ͺ͵Ͳ
using Image J. An increase in E6E7 transcript was observed in ∆CTCF HPV18 lines established ͺ͵ͳ
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from individual donors (donor 1, * p = 0.03; donor 2, * p = 0.03). (C) Proteins extracted from ͺ͵ʹ
raft cultures were analyzed by western blot. Fold increase in virus protein expression ͺ͵͵
compared to wild type (normalized to GAPDH protein) is indicated below each membrane ͺ͵Ͷ
section. The images shown are representative of three technical repeats of lysates extracted ͺ͵ͷ
from two independent donor lines. (D) E2 protein localization (red in merged image; DNA is ͺ͵͸
blue) in raft sections of HFK, wild type and ∆CTCF HPV18 genome-containing lines. The ͺ͵͹
images shown are representative of two independent raft cultures of each individual donor ͺ͵ͺ
line. Scale bar = 10 ʅm. ͺ͵ͻ
 ͺͶͲ
Figure 10: Loss of CTCF binding causes aberrant splicing of early transcripts. RNA extracted ͺͶͳ
from 14-day-old raft cultures was converted to cDNA and amplified between nucleotide 121 ͺͶʹ
and 3517. (A) The products were gel purified and sequenced. A graphical representation of ͺͶ͵
the identified products is shown in (B). (C) The 195bp product was quantified using Image J ͺͶͶ
and relative amounts normalized to wild type levels for each donor. The data shown ͺͶͷ
represent the mean and standard error of RNA extracted from 3 independent raft cultures ͺͶ͸
from each donor (donor 1, *** p = 0.0008; donor 2, *** p = 0.0095).  ͺͶ͹
 ͺͶͺ
 ͺͶͻ
 ͺͷͲ
Amplicon Forward primer 5' to 3' Reverse Primer 5’ to 3’ Reference 
121-295 ATCCAACACGGCGACCCTAC GCAGCATGCGGTATACTGTCTCTA (14), this study 
121-3517 ATCCAACACGGCGACCCTAC ACGGACACGGTGCTGGAA (14) 
E1F1/E4R CAACAATGGCTGATCCAGAAG AGGTCCACAATGCTGCTTCT (15) 
Table 1: Primers used for HPV18 transcript analysis   ͺͷͳ
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Class Type Predicted motif 
Fragment 
Tested Name Motif sequence 
Confirmed
in vitro 
Relative strength 
of binding 
      from to         
High risk HPV18 843 754 943 18_1 ATTCCAGCAGCTGTTTCTGA No n.d. 
  AY262282.1  1205 1102 1297 18_2 CCATTAGGGG No n.d. 
    2989 2926 3117 18_3 AAACCACCAGGTGGTGCCAG Yes strong* 
    3487 3381 3575 18_4 CGGTGAGGGG No n.d. 
    3620 3527 3718 18_5 TTGCCTGTAGGTGTAGCTGC Yes medium 
    4505, 4537 4440 4638 18_6 and 18_7 CGTCCCCCAGTGGT/GTAACAATAGATGGGTCTGT Yes two medium bands 
    None 4947 5155 18_8 N/A No n.d. 
    None 5045 5253 18_9 N/A No n.d. 
    5473 5381 5577 18_10 CATACAGAGG Yes medium 
    5767 5655 5850 18_11 CACCACCTGCAGGA Yes medium 
  HPV16 1282 1216 1405 16_1 AACTCAGCAGATGTTACAGG No n.d. 
   NC_001526.2 2915 2852 3049 16_2 TAACCACCAAGTGGTGCCAA Yes strong* 
    5118 5000 5207 16_3 CGCCTAGAGG Yes weak 
    6127 6051 6278 16_4 CCTATAGGGG Yes weak 
    6514 6426 6600 16_5 GAACCACTAGGTGTAGGAA Yes weak 
    6859 6772 6957 16_6 CTCCCCCAGGAGGC Yes weak 
  HPV31 615 534 713 31_1 ATAACAGTGGAGGTCAGTT No n.d. 
   J04353.1 885 804 1008 31_2 TGGGGAGGGG No n.d. 
    1093 1029 1200 31_3 CATGCAGAGG No n.d. 
    1277 1182 1374 31_4 AACGCAGCAGATGGTACAGG No n.d. 
    2332 2230 2406 31_5 CAACCACTGGCTGATGCTAA No n.d. 
    2412 2357 2531 31_6 AATGCACTAGATGGCAACC Yes strong* 
    2853 2801 3015 31_7 TAACCACCAGGTGGTGCCAG Yes strong* 
    None 2894 3093 31_8 N/A No n.d. 
    5179 5077 5273 31_9 CCTTTAGGGG Yes strong 
    6431 6354 6540 31_10 CTACACCTAGCGGC Yes medium 
Low risk HPV6b 1357 1251 1460 6b_1 CATACAGAGG No n.d. 
   NC_001355.1 None 2801 3007 6b_2 N/A No n.d. 
    None 2887 3101 6b_3 N/A No n.d. 
    4789 4715 4913 6b_4 TGTGCAGGGG No n.d. 
    5018, 4987 4913 5102 6b_5 and 6b_6 CTATCACTAGATGATACCA/CCTATAGAGG No n.d. 
    5424 5317 5515 6b_7 GCAGCCACAAGAGGGTGCAT Yes strong 
    6109 5995 6199 6b_8 CAGCCATTAGGTGTGGGTGT No n.d. 
    6263 6179 6382 6b_9 CCCAAAGGGG Yes medium 
    7205, 7256 7155 7380 6b_10 and 6b_11 CGAATAGAGG/CGTTTAGGGG No n.d. 
  HPV11 1357 1295 1494 11_1 CATAGAGAGG No n.d. 
   FR872717.1 None 2801 3003 11_2 N/A No n.d. 
    None 2900 3104 11_3 N/A No n.d. 
    4058 3930 4153 11_4 TGCAAAGGGG Yes medium 
    4781 4709 4898 11_5 TGTGTAGGGG No n.d. 
    4920 4844 5041 11_6 CCACCTGTGGAGGCCAGTG Yes weak 
    5415 5330 5501 11_7 GCAGCCACTAGAGGGTGCAG Yes strong 
    6310 6243 6428 11_8 GTTCCAACGGGGGGCAGTC Yes weak 
    6635 6544 6738 11_9 GAGCCACTAGGTGTATGTA Yes weak, smear 
    6979 6872 7074 11_10 CCTCCACCAAATGGTACACT No n.d. 
 
Table 2: Prediction of CTCF binding in various HPV types and relative in vitro binding ͺͷʹ
affinity. The accession number of each HPV genome analyzed is indicated. The position in ͺͷ͵
the viral genome of the first nucleotide of each predicted motif is given along with the ͺͷͶ
specific fragment tested by EMSA. Where a fragment was tested that did not contain a ͺͷͷ
predicted motif, no position is given (none). Each fragment tested is named by HPV type ͺͷ͸
followed by the order of position in the genome starting at position 1 in the URR. The ͺͷ͹
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sequence of each motif is given (N/A indicates that a motif was not predicted). Fragments ͺͷͺ
were tested for binding in vitro by EMSA. The relative strength of binding to each fragment ͺͷͻ
was assessed qualitatively by comparison to the proportion of c-Myc positive control DNA ͺ͸Ͳ
bound by CTCF in the same assay (weak, <50% binding; medium, 50-75% binding; strong, ͺ͸ͳ
>75% binding; n.d. = none detected). All EMSA experiments were repeated at least three ͺ͸ʹ
times and the strength of binding reflects the relative binding strength achieved in all ͺ͸͵
repeats. *CTCF binding site within the E2 ORF that is conserved in all high-risk HPV types ͺ͸Ͷ
tested.  ͺ͸ͷ
 
 
      Donor 1 Donor 2   
Primers Splice(s) Product size Fold change p Fold Change p Inferred ORFs 
121/295 Unspliced Early 175 1.65±0.27a 0.03 2.47±0.57 0.03 E6, E7  
E1F1/E4R 929^3434 190 1.049±0.086 0.58 1.058±0.26 0.83 E1^E4, E5 
121/3517 233^416, 929^3434 708 1.03±0.1 0.75 0.98±0.008 0.07 E6*I, E7, E1^E4, E5 
121/3517 233^3434 195 0.37±0.087b 0.0008 0.59±0.11 0.009 E6*II, E5 
 
 
Table 3: Analysis of splicing events in early transcripts produced in organotypic raft ͺ͸͸
culture. RNA extracted from 14-day-old raft cultures was converted to cDNA and amplified ͺ͸͹
with the indicated primer pairs. The fold change in transcript level compared to wild type ͺ͸ͺ
HPV18 rafts is shown as the mean and standard error of three independent repeats. ͺ͸ͻ
Significance (p) was calculated using a student’s T-test. aIndicates a significant increase in ͺ͹Ͳ
expression levels. bIndicates a significant decrease in expression levels compared to wild ͺ͹ͳ
type.  ͺ͹ʹ
 










